Last reviewed · How we verify
High dose Atorvastatin+enoxaparin
This combination reduces cholesterol synthesis via statin activity while simultaneously inhibiting thrombin and factor Xa to prevent blood clot formation.
This combination reduces cholesterol synthesis via statin activity while simultaneously inhibiting thrombin and factor Xa to prevent blood clot formation. Used for Acute coronary syndrome with hyperlipidemia, Secondary prevention of cardiovascular events in high-risk patients.
At a glance
| Generic name | High dose Atorvastatin+enoxaparin |
|---|---|
| Sponsor | Hallym University Medical Center |
| Drug class | Statin + Low-molecular-weight heparin combination |
| Target | HMG-CoA reductase (atorvastatin); Factor IIa and Factor Xa (enoxaparin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atorvastatin (a statin) competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby lowering LDL cholesterol and reducing atherosclerotic plaque formation. Enoxaparin is a low-molecular-weight heparin that potentiates antithrombin III, inactivating factors IIa and Xa to prevent thrombosis. Together, they address both lipid management and acute anticoagulation in cardiovascular disease.
Approved indications
- Acute coronary syndrome with hyperlipidemia
- Secondary prevention of cardiovascular events in high-risk patients
Common side effects
- Myalgia or muscle pain
- Elevated liver enzymes
- Bleeding or bruising
- Injection site reactions
- Headache
Key clinical trials
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose Atorvastatin+enoxaparin CI brief — competitive landscape report
- High dose Atorvastatin+enoxaparin updates RSS · CI watch RSS
- Hallym University Medical Center portfolio CI